References
- World Health Organization. Hepatitis B. Fact Sheet No. 204. Available from http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed August 5, 2016.
- NCBI. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Genev: World Health Organization; 2015 Mar. Available from http://www.ncbi.nlm.nih.gov/books/NBK305553/. Accessed August 5, 2016.
- Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10(1):1-98.
- Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30(12):2212-9. https://doi.org/10.1016/j.vaccine.2011.12.116
- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2095-128. https://doi.org/10.1016/S0140-6736(12)61728-0
- Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015;386(10003):1546-55. https://doi.org/10.1016/S0140-6736(15)61412-X
- Ministry of Health and Welfare. 2014 Korea Natinal Health & Nutrition Examination Survey VI 2nd. Available from http://stat.mohw.go.kr/. Accessed August 3, 2016.
- Lee JM, Ahn SH, Chang HY, et al. Reappraisal of HBV genotypes and clinical significance in Koreans using MALDI-TOF mass spectrometry. Korean J Hepatol 2004;10(4):260-70.
- Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol 2014;20(18):5427-34. https://doi.org/10.3748/wjg.v20.i18.5427
- Kim H, Jee YM, Song BC, et al. Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology 2007;50(1):52-7. https://doi.org/10.1159/000096313
- The Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22(1):18-75. https://doi.org/10.3350/cmh.2016.22.1.18
- Su MH, Lu AL, Li SH, et al. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. World J Gastroenterol 2015;21(46):13087-94. https://doi.org/10.3748/wjg.v21.i46.13087
- Kong HK, Shon HS, Choi KE, et al. Prescribing Patterns of Antivirals for Chronic Hepatitis B. Kor J Clin Pharm 2012;22(1):81-6.
- Jeong JY. Current and future of reimbursement criteria in liver disease:Reimbursement status of drugs for the treatment of hepatitis B in Asia countries and the situation and prospects in Korea. Taehan Kan Hakhoe Chi 2012;2012(2):84-9.
- Ministry of Health and Welfare Notification No.2013-75. Amendment of details of applicable standards and methods of reimbursement (drugs). Available from http://www.mohw.go.kr/front_new/jb/sjb0406ls.jsp?PAR_MENU_ID=03&MENU_ID=030406. Accessed July 25, 2016.
- The Korean Association for the Study of the Liver. KASL clinical practice guidelines update: management of chronic hepatitis B drug resistance. Available from http://www.kasl.org/bbs/index.html?code=guide&category=&gubun=&idx=\&page=1&number=2160&mode=view&order=&sort=&keyfield=&key=. Accessed July 27, 2016.
- Ministry of Health and Welfare Notification No.2015-68. Amendment of details of applicable standards and methods of reimbursement (drugs). Available from http://www.mohw.go.kr/front_new/jb/sjb 040 6ls.jsp?PAR_MENU_ID=03&MENU_ID=030406 Accessed August 7, 2016
- Kim R. Introduction of Health Insurance Review and Assessment services' national patients sample. HIRA Policy Trends 2012;6:37-47.
- Park SH. Trends in the seroprevalence of hepatitis B surface antigen in the South Korean population. Int J Infect Dis 16(9):e669-e72. https://doi.org/10.1097/00006454-200007000-00024
- Park B, Jung KW, Oh CM, et al. Ten-Year Changes in the Hepatitis B Prevalence in the Birth Cohorts in Korea: Results From Nationally Representative Cross-Sectional Surveys. Medicine 2015;94(41):e1469. https://doi.org/10.1097/MD.0000000000001469
- The Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2012;18(2):109-62. https://doi.org/10.3350/cmh.2012.18.2.109
- Yim HJ, Hwang SG. Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clin Mol Hepatol 2013;19(3):195-209. https://doi.org/10.3350/cmh.2013.19.3.195
- Wiens A, Lenzi L, Venson R, et al. Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis. Pharmacotherapy 2013;33(2):144-51. https://doi.org/10.1002/phar.1188
- Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 2012;35(6):674-89. https://doi.org/10.1111/j.1365-2036.2011.04990.x
- Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126(1):91-101. https://doi.org/10.1053/j.gastro.2003.10.051
- Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45(2):307-13. https://doi.org/10.1002/hep.21534